<DOC>
	<DOCNO>NCT00101127</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel gemcitabine , work different way stop growth tumor cell , either kill cell stop divide . Colony-stimulating factor , G-CSF pegfilgrastim , may increase number immune cell find bone marrow peripheral blood may help immune system recover side effect chemotherapy . Giving docetaxel gemcitabine together G-CSF pegfilgrastim may kill tumor cell . PURPOSE : This phase II trial study well give docetaxel gemcitabine together G-CSF pegfilgrastim work treat patient advance , persistent , recurrent uterine leiomyosarcoma .</brief_summary>
	<brief_title>Docetaxel , Gemcitabine , Filgrastim ( G-CSF ) Pegfilgrastim Treating Patients With Advanced , Persistent , Recurrent Uterine Leiomyosarcoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor activity docetaxel , gemcitabine , filgrastim ( G-CSF ) pegfilgrastim patient advance , persistent , recurrent uterine leiomyosarcoma . - Determine nature degree toxicity regimen patient . OUTLINE : This multicenter study . Patients stratify accord prior pelvic radiotherapy ( yes v ) . Patients receive gemcitabine IV 90 minute day 1 8 docetaxel IV 1 hour day 8 . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) day 9-15 OR pegfilgrastim SC day 9 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 12-43 patient accrue study within 12-28 month .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm uterine leiomyosarcoma Advanced , persistent , recurrent disease Documented disease progression Measurable disease At least 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan At least 1 target lesion Tumors within previously irradiate field consider nontarget lesion Ineligible high priority GOG protocol ( i.e. , active phase III GOG protocol patient population ) PATIENT CHARACTERISTICS : Age Adult Performance status GOG 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN Renal Creatinine ≤ 1.5 time ULN Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No neuropathy ( sensory motor ) &gt; grade 1 No invasive malignancy within past 5 year except nonmelanoma skin cancer No active infection require antibiotic No know hypersensitivity E. coliderived protein PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior cytotoxic chemotherapy malignancy Endocrine therapy At least 1 week since prior hormonal therapy malignancy Concurrent hormone replacement therapy allow Radiotherapy See Disease Characteristics Recovered prior radiotherapy Surgery Recovered prior surgery Other Recovered prior therapy No prior cancer treatment would preclude study treatment No concurrent amifostine protective agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>stage III uterine sarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>uterine leiomyosarcoma</keyword>
</DOC>